-
Professor Liang Wang:Advances in Ocular Lymphoma Research | Inaugural Academic Forum of the Ocular Lymphoma Collaborative Group
Ocular lymphoma is the most common malignant tumor within the orbit in adults, and its pathological diagnosis and classification are complex, often leading to missed and misdiagnosed cases. Improving the diagnosis rate of ocular lymphoma to better protect patients’ ocular and overall health is a significant challenge for ophthalmologists. On March 30, 2024, the inaugural…
-
Professor Hongyan Tong:Progress in Myelodysplastic Syndromes Research, Current Challenges, and Treatment Strategies | Seventh Beijing Thrombosis and Hemostasis Conference and Fifth Beijing Hematology Oncology and Immunology Summit Forum
From March 2nd to 3rd, 2024, the “Seventh Beijing Thrombosis and Hemostasis Conference and the Fifth Beijing Hematology Oncology and Immunology Summit Forum” was successfully held in Beijing. The event was organized by the National Clinical Research Center for Hematologic Diseases – Peking University Institute of Hematology and the Chinese Academy of Medical Sciences Peking…
-
EBMT China’s Voice | Professor Ruijuan Sun’s Team:Enhancing Pre-Treatment Protocols in allo-HSCT to Effectively Reduce Relapse Rates in High-Risk AML
Editor’s Note: Since 2008, the World Health Organization (WHO) has recognized t(6;9)(p22;q34)/DEK-NUP214 fusion gene-positive acute myeloid leukemia (AML) as a distinct subtype. This type of AML is characterized by a low incidence rate, high malignancy, a high risk of relapse after chemotherapy, and very poor prognosis. Hematopoietic stem cell transplantation can significantly improve these poor…
-
EBMT China Voice | Professor Ruijuan Sun:Comparing the Efficacy and Safety of Post-CD7 CAR-T vs. Post-Chemotherapy CR as a Bridge to Allo-HSCT in Pediatric T-ALL
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held with great fanfare in Glasgow, UK, from April 14 to 17, 2024. The conference focused on the latest advancements in stem cell transplantation and cellular therapy, pushing forward better clinical outcomes for patients with blood diseases and hematological malignancies.…
-
EAU24 Interview丨Dr. Junlong Zhuang and Dr. Bertrand Tombal jointly interpret the ARASENS study and explore intensive treatment strategies for mHSPC
Dr. Junlong Zhuang Drum Tower hospital Dr. Bertrand Tombal Université Catholique de Louvain (UCL) Oncology Frontier: Good morning, Dr. Tombal. The ARASENS study has demonstrated that the combination of ADT…
-
EAU24 Interview | Dr. Jens Bedke：Innovations in Advanced Urothelial Carcinoma Treatment
Dr. Jens Bedke Klinikum Stuttgart Katharinen Hospital Urology Frontier：Currently, platinum-based combination chemotherapy is still the first-line standard treatment for advanced urothelial carcinoma（UC）. What unmet needs do you think exist for…
-
EAU24 Interview丨Dr. Vasileios Sakalis：The value of artificial intelligence in the diagnosis and treatment of urinary tumors
Vasileios Sakalis MSc, PhD, FEBU, FRCS Consultant at Hippokration General Hospital, Thessaloniki Oncology Frontier：How accurate do you think current AI is in the field of urological cancers? Dr. Vasileios Sakalis:…
-
EBMT Distinguished Interview | Professor Jun Ma Reflects on 42 Years with EBMT
From April 14 to 17, 2024, the 50th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) was grandly held in Glasgow, UK. This year marks the 50th anniversary of EBMT, and the event brought together leaders in the field of hematopoietic stem cell transplantation and over 6,000 hematology experts from around…
Connecting Medical Expertise through Media